217 related articles for article (PubMed ID: 23664987)
1. Safety and immunogenicity of IMVAMUNE® smallpox vaccine using different strategies for a post event scenario.
Frey SE; Winokur PL; Salata RA; El-Kamary SS; Turley CB; Walter EB; Hay CM; Newman FK; Hill HR; Zhang Y; Chaplin P; Tary-Lehmann M; Belshe RB
Vaccine; 2013 Jun; 31(29):3025-33. PubMed ID: 23664987
[TBL] [Abstract][Full Text] [Related]
2. Phase II randomized, double-blinded comparison of a single high dose (5×10(8) TCID50) of modified vaccinia Ankara compared to a standard dose (1×10(8) TCID50) in healthy vaccinia-naïve individuals.
Frey SE; Winokur PL; Hill H; Goll JB; Chaplin P; Belshe RB
Vaccine; 2014 May; 32(23):2732-9. PubMed ID: 24607004
[TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
Walsh SR; Wilck MB; Dominguez DJ; Zablowsky E; Bajimaya S; Gagne LS; Verrill KA; Kleinjan JA; Patel A; Zhang Y; Hill H; Acharyya A; Fisher DC; Antin JH; Seaman MS; Dolin R; Baden LR
J Infect Dis; 2013 Jun; 207(12):1888-97. PubMed ID: 23482644
[TBL] [Abstract][Full Text] [Related]
4. Repeated high-dose (5 × 10(8) TCID50) toxicity study of a third generation smallpox vaccine (IMVAMUNE) in New Zealand white rabbits.
Tree JA; Hall G; Rees P; Vipond J; Funnell SG; Roberts AD
Hum Vaccin Immunother; 2016 Jul; 12(7):1795-801. PubMed ID: 26836234
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.
Kennedy JS; Gurwith M; Dekker CL; Frey SE; Edwards KM; Kenner J; Lock M; Empig C; Morikawa S; Saijo M; Yokote H; Karem K; Damon I; Perlroth M; Greenberg RN
J Infect Dis; 2011 Nov; 204(9):1395-402. PubMed ID: 21921208
[TBL] [Abstract][Full Text] [Related]
6. A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.
Greenberg RN; Hay CM; Stapleton JT; Marbury TC; Wagner E; Kreitmeir E; Röesch S; von Krempelhuber A; Young P; Nichols R; Meyer TP; Schmidt D; Weigl J; Virgin G; Arndtz-Wiedemann N; Chaplin P
PLoS One; 2016; 11(6):e0157335. PubMed ID: 27327616
[TBL] [Abstract][Full Text] [Related]
7. Sex difference in immune response to vaccination: A participant-level meta-analysis of randomized trials of IMVAMUNE smallpox vaccine.
Troy JD; Hill HR; Ewell MG; Frey SE
Vaccine; 2015 Oct; 33(41):5425-5431. PubMed ID: 26319063
[TBL] [Abstract][Full Text] [Related]
8. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
9. Comparison of lyophilized versus liquid modified vaccinia Ankara (MVA) formulations and subcutaneous versus intradermal routes of administration in healthy vaccinia-naïve subjects.
Frey SE; Wald A; Edupuganti S; Jackson LA; Stapleton JT; El Sahly H; El-Kamary SS; Edwards K; Keyserling H; Winokur P; Keitel W; Hill H; Goll JB; Anderson EL; Graham IL; Johnston C; Mulligan M; Rouphael N; Atmar R; Patel S; Chen W; Kotloff K; Creech CB; Chaplin P; Belshe RB
Vaccine; 2015 Sep; 33(39):5225-34. PubMed ID: 26143613
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.
von Krempelhuber A; Vollmar J; Pokorny R; Rapp P; Wulff N; Petzold B; Handley A; Mateo L; Siersbol H; Kollaritsch H; Chaplin P
Vaccine; 2010 Feb; 28(5):1209-16. PubMed ID: 19944151
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of a modified vaccinia Ankara vaccine using three immunization schedules and two modes of delivery: A randomized clinical non-inferiority trial.
Jackson LA; Frey SE; El Sahly HM; Mulligan MJ; Winokur PL; Kotloff KL; Campbell JD; Atmar RL; Graham I; Anderson EJ; Anderson EL; Patel SM; Fields C; Keitel W; Rouphael N; Hill H; Goll JB
Vaccine; 2017 Mar; 35(13):1675-1682. PubMed ID: 28256358
[TBL] [Abstract][Full Text] [Related]
12. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.
Frey SE; Newman FK; Kennedy JS; Sobek V; Ennis FA; Hill H; Yan LK; Chaplin P; Vollmar J; Chaitman BR; Belshe RB
Vaccine; 2007 Dec; 25(51):8562-73. PubMed ID: 18036708
[TBL] [Abstract][Full Text] [Related]
13. IMVAMUNE: modified vaccinia Ankara strain as an attenuated smallpox vaccine.
Kennedy JS; Greenberg RN
Expert Rev Vaccines; 2009 Jan; 8(1):13-24. PubMed ID: 19093767
[TBL] [Abstract][Full Text] [Related]
14. Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: vaccinia Tiantan strain.
Lu B; Yu W; Huang X; Wang H; Liu L; Chen Z
J Biomed Biotechnol; 2011; 2011():970424. PubMed ID: 21765641
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.
Wilck MB; Seaman MS; Baden LR; Walsh SR; Grandpre LE; Devoy C; Giri A; Kleinjan JA; Noble LC; Stevenson KE; Kim HT; Dolin R
J Infect Dis; 2010 May; 201(9):1361-70. PubMed ID: 20350191
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and safety of simplified vaccination schedules for the CYD-TDV dengue vaccine in healthy individuals aged 9-50 years (CYD65): a randomised, controlled, phase 2, non-inferiority study.
Coronel-MartÍnez DL; Park J; López-Medina E; Capeding MR; Cadena Bonfanti AA; Montalbán MC; Ramírez I; Gonzales MLA; DiazGranados CA; Zambrano B; Dayan G; Savarino S; Chen Z; Wang H; Sun S; Bonaparte M; Rojas A; Ramírez JC; Verdan MA; Noriega F
Lancet Infect Dis; 2021 Apr; 21(4):517-528. PubMed ID: 33212067
[TBL] [Abstract][Full Text] [Related]
17. Smallpox vaccine, ACAM2000: Sites and duration of viral shedding and effect of povidone iodine on scarification site shedding and immune response.
Pittman PR; Garman PM; Kim SH; Schmader TJ; Nieding WJ; Pike JG; Knight R; Johnston SC; Huggins JW; Kortepeter MG; Korman L; Ranadive M; Quinn X; Meyers MS
Vaccine; 2015 Jun; 33(26):2990-6. PubMed ID: 25930115
[TBL] [Abstract][Full Text] [Related]
18. An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies.
Wiser I; Balicer RD; Cohen D
Vaccine; 2007 Jan; 25(6):976-84. PubMed ID: 17074424
[TBL] [Abstract][Full Text] [Related]
19. Freeze-dried live attenuated smallpox vaccine prepared in cell culture "LC16-KAKETSUKEN": Post-marketing surveillance study on safety and efficacy compliant with Good Clinical Practice.
Nishiyama Y; Fujii T; Kanatani Y; Shinmura Y; Yokote H; Hashizume S
Vaccine; 2015 Nov; 33(45):6120-7. PubMed ID: 26455406
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model.
Garza NL; Hatkin JM; Livingston V; Nichols DK; Chaplin PJ; Volkmann A; Fisher D; Nalca A
Vaccine; 2009 Sep; 27(40):5496-504. PubMed ID: 19632316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
